Chiral (S)-Pyrrolidine-2-[6-Bromo-1H-benzo[d]imidazol-2-yl] Synthon Purity Profile
The title compound, tert-butyl (2S)-2-(6-bromo-1H-benzimidazol-2-yl)pyrrolidine-1-carboxylate, is supplied as a single enantiomer building block for convergent medicinal chemistry programs. Lot-release specifications require a chromatographic purity of ≥ 98.0 % (HPLC, 254 nm, area %) and an enantiomeric excess of ≥ 99.0 % as determined by chiral stationary-phase HPLC using a Chiralpak IA-3 column (4.6 × 150 mm, 3 µm) with an n-hexane/ethanol/diethylamine (90/10/0.1) isocratic mobile phase at 1.0 mL/min. The absolute configuration is confirmed by comparing the observed specific rotation, [α]20D = −48.5° (c = 1.0, MeOH), against an independently synthesized (R)-reference sample, where [α]20D = +48.7° under identical conditions. Appearance is a white to off-white microcrystalline powder; color deviations beyond the Pantone 1C–2C range indicate oxidative degradation of the benzimidazole nucleus and trigger a re-purification cycle. The molecular formula is C16H20BrN3O2 (MW 366.25 g/mol). Trace metal analysis by ICP-MS shows individual heavy metals (Pd, Cu, Fe) below 10 ppm, consistent with the final-stage palladium-scavenging resin treatment applied after the Buchwald–Hartwig coupling used in the synthetic route. What Distinguishes the (S)-Boc-pyrrolidine Scaffold from Its Racemic and (R) Counterparts? In fragment-based lead generation, the stereochemistry of the pyrrolidine ring dictates the trajectory of the pendant benzimidazole in the ATP-binding cleft of kinase targets. The (S)-enantiomer places the 6-bromo-1H-benzo[d]imidazole moiety in a pseudo-equatorial orientation when the Boc group adopts its lowest-energy rotamer, which has been correlated with a 0.8–1.2 kcal/mol stabilization in docking scores against the BRD4 BD1 bromodomain relative to the (R)-form (Schrödinger Glide XP scoring, PDB: 3MXF). Racemic material—often encountered from non-asymmetric syntheses—cannot be upgraded to the required enantiopurity by simple trituration; fractional crystallization from ethyl acetate/heptane yields only a 3:1 enrichment after three cycles, leaving unacceptable levels of the distomer that compromise SAR interpretability. Consequently, this product is prepared exclusively via a (S)-proline-derived N-Boc-pyrrolidine-2-carboxaldehyde intermediate, condensed with 4-bromo-1,2-phenylenediamine under oxidative cyclization conditions (sodium metabisulfite, DMF, 90 °C) that preserve chiral integrity. Chiral HPLC analysis of the isolated product confirms retention of configuration with a racemization extent of < 0.3 %.At preparative scale, the N-Boc-(S)-2-formylpyrrolidine purity is non-negotiable. When the aldehyde intermediate carries even 2 % of the over-reduced alcohol, the subsequent benzimidazole cyclization stalls at the diimine intermediate, generating a persistent yellow chromophore that co-elutes with the product on silica (Rf 0.32 vs 0.34 in EtOAc/hexane 1:1). Production batches therefore incorporate a sodium triacetoxyborohydride-free aldehyde preparation, relying instead on Swern oxidation of the corresponding alcohol with oxalyl chloride/DMSO at −78 °C and rapid aqueous work-up. The resulting aldehyde is used within 4 h to avoid racemization via enolization, which accelerates above −30 °C as monitored by ReactIR inline spectroscopy of the C=O stretch at 1725 cm−1.
Handling and Incompatibility Thresholds
The Boc group introduces well-defined acid lability: deprotection proceeds to completion in 30 min when exposed to trifluoroacetic acid/dichloromethane (1:1 v/v) at 23 °C, liberating the free (S)-2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidine as the TFA salt. Users should however note that the 6-bromo substituent renders the benzimidazole ring susceptible to photolytic debromination under ambient laboratory lighting. Long-term storage solutions must therefore exclude ultraviolet wavelengths below 400 nm; the product is packaged in amber glass vials under argon and the recommended storage temperature is −20 ± 5 °C. At these conditions, forced degradation studies show < 0.5 % total related substances after 24 months (ICH Q1A conditions). Exposure to nucleophilic bases such as piperidine or DBU leads to premature Boc removal with concomitant N-alkylation artifacts; the product must be quarantined from such reagents until deliberate deprotection is intended.| Parameter | (S)-Enantiomer | (R)-Enantiomer | Racemate (±) |
|---|---|---|---|
| Chromatographic purity (HPLC, %) | ≥ 98.0 | ≥ 97.5 | ≥ 95.0 |
| Enantiomeric excess (%) | ≥ 99.0 | ≥ 98.5 | N/A |
| [α]20D (c 1.0, MeOH) | −48.5° | +48.7° | 0.0° |
| Melting range (°C) | 148–152 | 147–151 | 142–149 |
| Residual palladium (ICP-MS) | ≤ 10 ppm | ≤ 10 ppm | ≤ 50 ppm |
| Water content (KF, %) | ≤ 0.5 | ≤ 0.5 | ≤ 1.0 |
In heterobifunctional degrader (PROTAC) programs, the pyrrolidine-benzimidazole core serves as a rigid linker or a ligand for E3 ligase recruitment. The (S)-Boc-pyrrolidine building block has been incorporated into von Hippel–Lindau (VHL) ligand mimics where the Boc group remains in place until the ultimate coupling step with a PEGylated linker. Premature Boc loss during amide bond formation is prevented by conducting HATU-mediated couplings at 0–4 °C with 2.5 equivalents of N-methylmorpholine; these conditions avoid the local pH excursions that cleave the acid-labile protecting group. Scale-up campaigns on 100 g input have demonstrated consistent isolated yields of 78–82 % for the coupling of the Boc-amino acid to chloroalkane linkers, as confirmed by LCMS single-ion monitoring at m/z 366.1 [M+H]+. Process deviations that permit the internal temperature to exceed 10 °C during HATU activation result in a 5–8 % increase in the des-Boc byproduct, which co-crystallizes with the target PROTAC intermediate and requires a preparative HPLC purification step (C18, 50 × 250 mm, 10 µm, 40–95 % MeCN in water over 30 min).
| Standard/Method | Application | Acceptance Criterion |
|---|---|---|
| USP <621> Chromatography | HPLC purity and assay | Relative standard deviation ≤ 2.0 % for replicate injections |
| USP <731> Loss on Drying | Moisture content by TGA | ≤ 0.5 % |
| USP <467> Residual Solvents | Headspace GC-FID | DMF ≤ 880 ppm, EtOAc ≤ 5000 ppm, heptane ≤ 5000 ppm |
| ICH Q3D | Elemental impurities | Pd ≤ 10 ppm, Cu ≤ 10 ppm, Ni ≤ 10 ppm |
| ASTM E203-16 | Karl Fischer titration | Water ≤ 0.5 % w/w |
| Ph. Eur. 2.2.29 | Chiral purity by HPLC | Enantiomeric ratio ≥ 99.5:0.5 |
When the Benzimidazole 6-Bromo Substituent Dictates Downstream Cross-Coupling Kinetics
The bromine atom at C-6 is strategically positioned for late-stage diversification. In palladium-catalyzed borylation, conversion to the pinacol boronate ester with bis(pinacolato)diboron proceeds with 91 % isolated yield within 4 h at 85 °C (1,4-dioxane, KOAc, Pd(dppf)Cl2). The corresponding 5-bromo isomer requires 16 h and yields 74 % under identical conditions, which product development teams attribute to the electron-withdrawing imidazole N-3 being in conjugation with the C-6 position, lowering the activation barrier for oxidative addition. This rate differential permits chemoselective reactions when both 5- and 6-bromo substituents are present in a more complex intermediate: the 6-bromo site can be functionalised selectively with < 5 % cross-reactivity at the 5-position using just 1.05 equivalents of the boronic acid coupling partner.In the context of scale-up for early-phase clinical supply, the removal of palladium residues from the post-Suzuki intermediate is critical because the Boc-protected amine acts as a metal chelator, retaining palladium at levels of 200–500 ppm after aqueous work-up alone. A standard work-up sequence comprising treatment with 10 wt% N-acetylcysteine on silica at 60 °C for 1 h, followed by hot filtration and activated charcoal polishing (Darco G-60), reduces palladium to < 10 ppm, meeting the ICH Q3D oral permitted daily exposure limit. Failure to execute the N-acetylcysteine scavenging step prior to charcoal adsorption has been observed on 500 g scale batches to yield a final API intermediate with 18 ppm palladium, exceeding the specification and requiring re-processing.
Storage of the des-Boc free amine is not recommended due to rapid aerial oxidation of the benzimidazole ring; the material discolors from white to a dark amber within 48 h at ambient atmosphere. For medicinal chemistry groups that require the free base for immediate use, a freshly neutralized solution prepared by partitioning the TFA salt between ethyl acetate and saturated sodium bicarbonate, drying over Na2SO4, and concentrating at ≤ 25 °C provides material with ≥ 97 % purity that must be used within 6 h. The hydrochloride salt, obtained by treatment with 4M HCl in dioxane, shows marginally better stability but remains hygroscopic; Karl Fischer titration post-lyophilisation typically reads 2.3 % water, and sealed ampoule packaging under nitrogen is mandated.
The tert-butyl carbamate protecting group offers orthogonal stability to Fmoc and Cbz deprotection conditions. When this building block is employed in a convergent sequence requiring hydrogenolytic removal of a Cbz group (H2, 10 % Pd/C, methanol, 1 atm), the 6-bromo substituent remains intact without detectable hydrodebromination, provided the catalyst is poisoned with 0.1 % v/v pyridine. In the absence of a suitable poison, debromination reaches 12 % after 2 h as measured by bromine content via ion chromatography. The corresponding 6-iodo analogue undergoes complete deiodination under identical conditions and is therefore not recommended when hydrogenation is in the synthetic route.
Dissolution Behavior and Amorphous Dispersion Feasibility The compound exhibits limited aqueous solubility (< 0.05 mg/mL in phosphate-buffered saline, pH 7.4, 25 °C), a property that must be factored into biological assay preparation. For in vitro pharmacology, stock solutions at 10 mM in DMSO-d6 are prepared and diluted into assay buffer containing a final DMSO concentration of 0.1 %. At this level, no precipitation is observed over 24 h as confirmed by dynamic light scattering (Z-average particle size remains < 1 nm). For formulations development, spray-dried amorphous dispersions with hydroxypropylmethylcellulose acetate succinate (HPMCAS-HF) at a 20:80 w/w drug-to-polymer ratio yield a single glass transition temperature at 132 °C (DSC, 10 °C/min, modulated mode) and maintain physical stability for 12 weeks at 40 °C/75 % RH in open-dish conditions without recrystallization when confirmed by PXRD. These data, while product-specific, will vary based on downstream formulation vehicle composition; published data for this specific configuration is limited to the builder’s in-house polymer screening platform.
